Artificial Accessory Cell Platform for Stem Cell Culture

用于干细胞培养的人工辅助细胞平台

• 批准号: 8251861
• 负责人: TODD A MCADAMS
• 金额: $ 21.73万
• 依托单位: RESODYN CORPORATION
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-10 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8251861
• 关键词: Antigen-Presenting Cells; Antigens; Binding; Biological; Biological Assay; Biological Preservation; Blood Circulation; Caliber; Cell Culture System; Cell Culture Techniques; Cells; Chemistry; Clinic; Cytoskeleton; Development; EGF gene; Effector Cell; Employee Strikes; Equilibrium; Erythrocyte Transfusion; Excision; Goals; Growth; Growth Factor; Growth Factor Receptors; Hematopoietic stem cells; Immobilization; Individual; Knowledge; Length; Life; Membrane; Methods; Microspheres; Mono-S; Particle Size; Pathway interactions; Peptides; Perfusion; Phagocytosis; Phase; Polymers; Polystyrenes; Preservation Technique; Production; Proteins; Protocols documentation; Reagent; Reporting; Research Personnel; Scientist; Signal Transduction; Signaling Molecule; Small Business Innovation Research Grant; Stem cells; Surface; Suspension Culture; System; Technology; Testing; Therapeutic; Time; Variant; Vision; Work; base; cell growth; cell type; cost; cytokine; density; feeding; in vivo; interest; large scale production; practical application; prevent; programs; protocol development; prototype; receptor; response; scale up; small molecule; stem cell differentiation; stem cell therapy

DESCRIPTION (provided by applicant): This Small Business Innovation Research Phase I project will develop and demonstrate a broad-application prototype Artificial Accessory Cell that can be used as a supplement and/or replacement for cytokines for the directed differentiation of stem cells into desired lineages. While the technology is applicable to all types of stem cells for which some information on its biological niche is available, the initial technology demonstration and suite of products will be focused on hematopoietic stem cells (HSCs) because of the extensive knowledge and range of cytokines available for this well-studied system. Immobilization of biologically active factors is essential to achieving the goal of efficiently directing stem cells along desired pathways for therapeutic aims. In vivo, many important cytokines are presented in membrane-bound, or extra-cellular matrix (ECM)- bound forms[1]. Presentation in this format often induces a unique biological response on the effectors cell that cannot be duplicated using soluble forms of the molecule. In addition, this strategy may be effective for limiting the quantity of expensive signaling molecules necessary for large-scale production of differentiated cells, such as the production of red blood cells for transfusion in an ex vivo format. While other investigators have developed much alternative chemistry for the covalent binding of cytokines to various types of substrates, the focus of this project is to develop and validate a stable, consistent, and commercializable microsphere-based system that can be applied as easily as soluble cytokines. PUBLIC HEALTH RELEVANCE: This Small Business Innovation Research Phase I project will develop and demonstrate the use of Artificial Accessory Cells (AACs) to help guide and control the differentiation of stem cells for therapeutic applications. In order to effectively scale-up and reduce the costs of bringing stem cell therapies to the clinic, more efficient means of providing the growth factors needed to guide stem cells are needed. Use of the proposed AACs has the potential to increase the efficacy and stability of these factors while reducing the costs for large-scale stem cell differentiation.

描述（由申请人提供）：这个小型企业创新研究阶段I项目将开发并展示一个广泛的原型人工辅助细胞，可以用作细胞因子的补充和/或替代细胞因子，以将干细胞的定向分化为所需的谱系。尽管该技术适用于所有类型的干细胞，但有关其生物生物位的一些信息可获得，但产品的初始技术演示和套件将集中在造血干细胞（HSC）上，因为该系统的广泛知识和细胞因子范围可用于此精心研究的系统。固定生物活性因子的固定对于实现有效指导干细胞沿所需途径的治疗目标的目标至关重要。在体内，许多重要的细胞因子呈现在膜结合或细胞外基质（ECM） - 结合形式[1]中。这种格式的呈现通常会引起对效应细胞的独特生物反应，该响应无法使用分子的可溶性形式重复。此外，该策略可能有效地限制了大规模生产分化细胞所需的昂贵信号分子的数量，例如以离体格式输血的红细胞产生。尽管其他研究者为细胞因子与各种类型的底物的共价结合开发了许多替代化学，但该项目的重点是开发和验证一个稳定，一致且可商业化的基于微球的系统，可以像溶解细胞因子一样轻松地应用。 公共卫生相关性：这个小型企业创新研究阶段I项目将开发并证明人工配件细胞（AAC）的使用来帮助指导和控制干细胞的治疗应用区分。为了有效扩大并降低将干细胞疗法带到诊所的成本，需要更有效地提供指导干细胞所需的生长因子的方法。拟议的AAC的使用有可能提高这些因素的功效和稳定性，同时降低大规模干细胞分化的成本。